Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter rasagiline pharmacogenomics study in Parkinson's disease
ChiCTR2500105342Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rasagiline in Parkinson's disease (PD), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: MDS-UPDRS Part III score difference. Started Jul 2025; status: recruiting.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2500105342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105342.